HALO vs. ABBV
HALO (Halozyme Therapeutics, Inc.) and ABBV (AbbVie Inc.) are both stocks. Both are in the Healthcare sector — HALO in Biotechnology, ABBV in Drug Manufacturers - General. Over the past 10 years, HALO returned 23.49%/yr vs 19.47%/yr for ABBV. At a 0.34 correlation, their price movements are largely independent.
Performance
HALO vs. ABBV - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, HALO achieves a 3.45% return, which is significantly lower than ABBV's 4.43% return. Over the past 10 years, HALO has outperformed ABBV with an annualized return of 23.49%, while ABBV has yielded a comparatively lower 19.47% annualized return.
HALO
- 1D
- 0.91%
- 1M
- 1.90%
- YTD
- 3.45%
- 6M
- 1.84%
- 1Y
- 31.86%
- 3Y*
- 26.81%
- 5Y*
- 8.86%
- 10Y*
- 23.49%
ABBV
- 1D
- 2.07%
- 1M
- 8.84%
- YTD
- 4.43%
- 6M
- 4.29%
- 1Y
- 31.92%
- 3Y*
- 24.36%
- 5Y*
- 19.80%
- 10Y*
- 19.47%
HALO vs. ABBV - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
HALO Halozyme Therapeutics, Inc. | 3.45% | 40.77% | 29.36% | -35.04% | 41.51% | -5.85% | 140.89% | 21.19% | -27.79% | 105.06% |
ABBV AbbVie Inc. | 4.43% | 33.08% | 18.86% | -0.23% | 24.01% | 32.43% | 27.72% | 1.47% | -0.96% | 60.07% |
Correlation
The correlation between HALO and ABBV is 0.31, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.31 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.28 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.28 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.33 |
Correlation (All Time) Calculated using the full available price history since Jan 2, 2013 | 0.34 |
Fundamentals
HALO:
$8.55B
ABBV:
$416.46B
HALO:
$2.87
ABBV:
$2.05
HALO:
24.30
ABBV:
114.38
HALO:
5.62
ABBV:
6.63
HALO:
38.95
ABBV:
15.14
HALO:
$1.51B
ABBV:
$62.82B
HALO:
$1.23B
ABBV:
$46.15B
HALO:
$980.05M
ABBV:
$17.96B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
HALO vs. ABBV — Risk / Return Rank
HALO
ABBV
HALO vs. ABBV - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Halozyme Therapeutics, Inc. (HALO) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| HALO | ABBV | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.22 | ||
| Sortino ratioReturn per unit of downside risk | -0.32 | ||
| Omega ratioGain probability vs. loss probability | 1.19 | 1.24 | -0.04 |
| Calmar ratioReturn relative to maximum drawdown | 1.33 | 1.85 | -0.53 |
| Martin ratioReturn relative to average drawdown | 2.47 | 4.11 | -1.64 |
Loading charts...
Drawdowns
HALO vs. ABBV - Drawdown Comparison
The maximum HALO drawdown since its inception was -74.26%, which is greater than ABBV's maximum drawdown of -45.09%. Use the drawdown chart below to compare losses from any high point for HALO and ABBV.
Loading charts...
Drawdown Indicators
| HALO | ABBV | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -74.26% | -45.09% | -29.17% |
Max Drawdown (1Y)Largest decline over 1 year | -24.13% | -17.32% | -6.81% |
Max Drawdown (3Y)Largest decline over 3 years | -33.92% | -20.74% | -13.18% |
Max Drawdown (5Y)Largest decline over 5 years | -49.06% | -21.92% | -27.14% |
Max Drawdown (10Y)Largest decline over 10 years | -49.06% | -45.09% | -3.97% |
Current DrawdownCurrent decline from peak | -14.29% | -1.66% | -12.63% |
Average DrawdownAverage peak-to-trough decline | -31.86% | -10.70% | -21.16% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.92% | 7.78% | +5.14% |
Volatility
HALO vs. ABBV - Volatility Comparison
Halozyme Therapeutics, Inc. (HALO) and AbbVie Inc. (ABBV) have volatilities of 8.95% and 9.26%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| HALO | ABBV | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.95% | 9.26% | -0.31% |
Volatility (6M)Calculated over the trailing 6-month period | 24.08% | 19.11% | +4.97% |
Volatility (1Y)Calculated over the trailing 1-year period | 30.35% | 25.23% | +5.12% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 39.44% | 23.12% | +16.32% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 42.74% | 25.83% | +16.91% |
Dividends
HALO vs. ABBV - Dividend Comparison
HALO has not paid dividends to shareholders, while ABBV's dividend yield for the trailing twelve months is around 2.87%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ABBV AbbVie Inc. | 2.87% | 2.87% | 3.49% | 3.82% | 3.49% | 3.84% | 4.41% | 4.83% | 3.89% | 2.65% | 3.64% | 3.41% |
HALO Halozyme Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
HALO vs. ABBV - Financials Comparison
This section allows you to compare key financial metrics between Halozyme Therapeutics, Inc. and AbbVie Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
HALO vs. ABBV - Profitability Comparison
HALO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a gross profit of 297.47M and revenue of 376.71M. Therefore, the gross margin over that period was 79.0%.
ABBV - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported a gross profit of 12.53B and revenue of 15.00B. Therefore, the gross margin over that period was 83.5%.
HALO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported an operating income of 184.52M and revenue of 376.71M, resulting in an operating margin of 49.0%.
ABBV - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported an operating income of 4.73B and revenue of 15.00B, resulting in an operating margin of 31.6%.
HALO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a net income of 150.05M and revenue of 376.71M, resulting in a net margin of 39.8%.
ABBV - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, AbbVie Inc. reported a net income of 699.00M and revenue of 15.00B, resulting in a net margin of 4.7%.
Frequently Asked Questions
HALO and ABBV have a correlation of 0.31, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ABBV has higher volatility (9.26%) compared to HALO (8.95%). In terms of maximum drawdown, HALO dropped -74.26% vs ABBV's -45.09%.
ABBV currently has the higher Sharpe Ratio (1.27 vs 1.05), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for HALO and ABBV
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer